Palbociclib, which is particularly confined to the ATP binding location of CDK4/6 proteins, prevents Rb phosphorylation, inhibits E2F transcription factor release, and blocks the cell cycle between G1 and S phases, and ultimately cease the growth of tumor cells. Here, CDK4 is linked to neoplasm.